Publicaciones en las que colabora con José A. Obeso Inchausti (21)

2024

  1. Calbindin and Girk2/Aldh1a1 define resilient vs vulnerable dopaminergic neurons in a primate Parkinson’s disease model

    npj Parkinson's Disease, Vol. 10, Núm. 1

2022

  1. Cerebral metabolic pattern associated with progressive parkinsonism in non-human primates reveals early cortical hypometabolism

    Neurobiology of Disease, Vol. 167

2015

  1. Editorial: Parkinson’s disease: Cell vulnerability and disease progression

    Frontiers in Neuroanatomy

  2. Monoaminergic PET imaging and histopathological correlation in unilateral and bilateral 6-hydroxydopamine lesioned rat models of Parkinson's disease: A longitudinal in-vivo study

    Neurobiology of Disease, Vol. 77, pp. 165-172

2012

  1. Functional neuroanatomy of the basal ganglia

    Cold Spring Harbor Perspectives in Medicine, Vol. 2, Núm. 12

  2. The nigrostriatal system in the presymptomatic and symptomatic stages in the MPTP monkey model: A PET, histological and biochemical study

    Neurobiology of Disease, Vol. 48, Núm. 1, pp. 79-91

2011

  1. Past, present, and future of the pathophysiological model of the basal ganglia

    Frontiers in Neuroanatomy

  2. Statistical parametric maps of 18F-FDG PET and 3-D autoradiography in the rat brain: A cross-validation study

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 38, Núm. 12, pp. 2228-2237

2010

  1. A direct projection from the subthalamic nucleus to the ventral thalamus in monkeys

    Neurobiology of Disease, Vol. 39, Núm. 3, pp. 381-392

  2. Progression of dopaminergic depletion in a model of MPTP-induced Parkinsonism in non-human primates. An 18F-DOPA and 11C-DTBZ PET study

    Neurobiology of Disease, Vol. 38, Núm. 3, pp. 456-463

2009

  1. New MRI, 18F-DOPA and 11C-(+)-α-dihydrotetrabenazine templates for Macaca fascicularis neuroimaging: Advantages to improve PET quantification

    NeuroImage, Vol. 47, Núm. 2, pp. 533-539

2008

  1. Immunotherapy for neurological diseases

    Clinical Immunology

  2. Lesion of the centromedian thalamic nucleus in MPTP-treated monkeys

    Movement Disorders, Vol. 23, Núm. 5, pp. 708-715

  3. Síntesis rápida y simplificada de 11C-(+)-α- dihidrotetrabenazina para su utilización como radioligando PET de los transportadores vesiculares de monoaminas

    Revista Espanola de Medicina Nuclear, Vol. 27, Núm. 1, pp. 13-21

  4. Utilización de la11C-(+)-α-dihidrotetrabenazina para la evaluación de la inervación dopaminérgica en modelos animales de la enfermedad de Parkinson

    Revista Espanola de Medicina Nuclear, Vol. 27, Núm. 2, pp. 103-111

2005

  1. Thalamic innervation of the direct and indirect basal ganglia pathways in the rat: Ipsi- and contralateral projections

    Journal of Comparative Neurology, Vol. 483, Núm. 2, pp. 143-153

2004

  1. How does Parkinson's disease begin? The role of compensatory mechanisms (multiple letters)

    Trends in Neurosciences

  2. Thalamic innervation of striatal and subthalamic neurons projecting to the rat entopeduncular nucleus

    European Journal of Neuroscience, Vol. 19, Núm. 5, pp. 1267-1277

  3. The origin of motor fluctuations in Parkinson's disease: Importance of dopaminergic innervation and basal ganglia circuits

    Neurology, Vol. 62, Núm. 1 SUPPL. 1

2002

  1. The parafascicular thalamic complex and basal ganglia circuitry: Further complexity to the basal ganglia model

    Thalamus and Related Systems, Vol. 1, Núm. 4, pp. 341-348